Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated: April 2, 2026, 3:24 am
Author: Getaka|Social: XLinkedIn
Stock Ticker - BSE: 524558 | NSE: NEULANDLAB

Neuland Laboratories Ltd: Intrinsic Value & Share Price Analysis

Fair Value

₹13,516.89Fairly Valued by 7.17%vs CMP ₹12,613.00

P/E (90.3) × ROE (14.8%) × BV (₹1,263.00) × DY (0.10%)

₹5,388.63Overvalued by 57.28%vs CMP ₹12,613.00
MoS: -134.1% (Negative)Confidence: 63/100 (Moderate)Models: 1 Under, 8 Over
ModelCategoryValueWeightSignal
PE-ROEEarnings₹16,615.9523%Under (+31.7%)
Graham NumberEarnings₹1,991.9017%Over (-84.2%)
Earnings PowerEarnings₹1,421.6211%Over (-88.7%)
DCFCash Flow₹3,216.5011%Over (-74.5%)
Net Asset ValueAssets₹1,262.707%Over (-90%)
EV/EBITDAEnterprise₹2,887.859%Over (-77.1%)
Earnings YieldEarnings₹1,396.207%Over (-88.9%)
ROCE CapitalReturns₹1,577.007%Over (-87.5%)
Revenue MultipleRevenue₹1,151.246%Over (-90.9%)
Consensus (9 models)₹5,388.63100%Overvalued
Key Drivers: Wide model spread (₹1,151–₹16,616) — high uncertainty.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: 22.9%

*Investments are subject to market risks

Investment Snapshot

56
Neuland Laboratories Ltd scores 56/100 (Average)
Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison
Stock Health77/100 · Strong
ROCE 18.7% GoodROE 14.8% GoodD/E 0.18 Low debtInterest Coverage 0.0x RiskyProfitable 5/5 years Consistent
Smart Money45/100 · Moderate
FII holding down -1.22% (6mo) SellingDII holding up 3.75% MF buyingPromoter holding at 32.6% Stable
Earnings Quality65/100 · Strong
OPM expanding (19% → 26%) Improving
Quarterly Momentum30/100 · Weak
Revenue (4Q): 3% YoY FlatProfit (4Q): -40% YoY DecliningOPM: 18.0% (down 4.0% YoY) Margin pressure
Industry Rank40/100 · Moderate
P/E 90.3 vs industry 53.8 Premium to peersROCE 18.7% vs industry 16.4% Average3Y sales CAGR: 16% Moderate

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily. Not investment advice.

Share Price and Basic Stock Data

Last Updated: April 2, 2026, 3:24 am

Market Cap 16,182 Cr.
Current Price 12,613
Intrinsic Value₹5,388.63
High / Low 19,748/10,060
Stock P/E90.3
Book Value 1,263
Dividend Yield0.10 %
ROCE18.7 %
ROE14.8 %
Face Value 10.0
PEG Ratio3.94

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Neuland Laboratories Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Neuland Laboratories Ltd 16,182 Cr. 12,613 19,748/10,06090.3 1,2630.10 %18.7 %14.8 % 10.0
Granules India Ltd 15,242 Cr. 628 640/41228.0 1640.24 %15.1 %13.9 % 1.00
Natco Pharma Ltd 17,945 Cr. 1,002 1,060/66011.5 4830.60 %32.8 %28.0 % 2.00
ERIS Lifesciences Ltd 18,152 Cr. 1,310 1,910/1,09740.9 2270.56 %12.2 %12.9 % 1.00
Alembic Pharmaceuticals Ltd 13,308 Cr. 677 1,108/63520.1 2711.62 %13.0 %11.4 % 2.00
Industry Average19,815.15 Cr1,053.8453.84201.200.39%16.35%15.16%6.10

All Competitor Stocks of Neuland Laboratories Ltd

Quarterly Result

MetricDec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales 269407363418393385440311398328293514440
Expenses 215287266280272278316249311277258359363
Operating Profit 54120971371211071236287513415677
OPM % 20%29%27%33%31%28%28%20%22%16%12%30%18%
Other Income 182325254607828
Interest 3424443122557
Depreciation 13131415151616161617202324
Profit before tax 39110831221049213049128391812954
Tax % 22%23%26%27%22%27%25%34%20%29%21%25%26%
Net Profit 318562898168983310228149741
EPS in Rs 23.8165.8948.2369.5663.4452.6676.2825.6079.1821.6810.8375.4931.62

Last Updated: March 3, 2026, 5:16 pm

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 25, 2026, 5:02 am

MetricMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 4664695105795276677639379511,1911,5591,4771,575
Expenses 3954024304724776086617908079181,0961,1461,257
Operating Profit 7167801065158102147144273463331318
OPM % 15%14%16%18%10%9%13%16%15%23%30%22%20%
Other Income 30214341609129025
Interest 2527242119162218141314819
Depreciation 15151619222631404953606684
Profit before tax 3525426714205310582216401346241
Tax % 23%36%36%30%13%19%69%23%22%24%25%25%
Net Profit 271627471216168164164300260179
EPS in Rs 30.1217.9630.7552.7413.5712.8112.6362.8549.74127.45233.89202.74139.62
Dividend Payout % 9%8%7%0%0%0%16%8%10%8%6%6%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)-40.74%68.75%74.07%-74.47%33.33%0.00%406.25%-20.99%156.25%82.93%-13.33%
Change in YoY Net Profit Growth (%)0.00%109.49%5.32%-148.54%107.80%-33.33%406.25%-427.24%177.24%-73.32%-96.26%

Neuland Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:12%
5 Years:14%
3 Years:16%
TTM:-19%
Compounded Profit Growth
10 Years:29%
5 Years:67%
3 Years:47%
TTM:-59%
Stock Price CAGR
10 Years:38%
5 Years:71%
3 Years:130%
1 Year:14%
Return on Equity
10 Years:12%
5 Years:16%
3 Years:19%
Last Year:15%

Last Updated: September 5, 2025, 11:40 am

Balance Sheet

Last Updated: December 4, 2025, 1:43 am

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 899991313131313131313
Reserves 1161521785375496866977748289811,2701,5121,607
Borrowings 19018818219231923126418224112895157265
Other Liabilities 169162155148194200257356302457454498649
Total Liabilities 4835125248861,0711,1301,2311,3251,3831,5801,8332,1802,534
Fixed Assets 1311231394664755426537167677588249551,076
CWIP 35414020126104241720414648140
Investments 77788887411109114
Other Assets 3113403373934634765475855927819621,0681,204
Total Assets 4835125248861,0711,1301,2311,3251,3831,5801,8332,1802,534

Reserves and Borrowings Chart

Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity + 4913453911705718960237261317
Cash from Investing Activity + -10-14-20-42-116-77-49-84-95-61-150-298
Cash from Financing Activity + -391-24-010512-5-11438-136-6925
Net Cash Flow -001-4-053-93404244
Free Cash Flow 38-126-2-1217984-37173119112
CFO/OP 74%33%70%52%28%128%61%132%56%103%81%119%

Free Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow-119.00-121.00-102.00-86.00-268.00-173.00-162.00-35.00-97.00145.00368.00174.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 9310085114134909185901118778
Inventory Days 138170182186266191209205227211220238
Days Payable 139167121118189118110126100129121156
Cash Conversion Cycle 92103147182211162190164216193187160
Working Capital Days -211126443844496074818876
ROCE %19%16%18%16%4%4%8%11%10%21%33%19%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters 36.14%36.03%35.97%32.80%32.74%32.72%32.64%32.68%32.67%32.67%32.64%32.63%
FIIs 18.14%20.19%21.57%22.69%24.43%25.72%26.46%23.86%22.12%21.69%20.60%20.90%
DIIs 7.10%6.76%6.99%6.02%6.54%6.39%6.38%9.09%10.97%11.57%13.55%14.72%
Government 0.40%0.40%0.40%0.40%0.40%0.40%0.40%0.40%0.40%0.40%0.40%0.00%
Public 38.22%36.62%35.08%38.10%35.88%34.77%34.12%33.96%33.85%33.67%32.80%31.76%
No. of Shareholders 26,94825,22326,82427,72328,61629,07734,56739,31539,33342,41944,39346,187

Shareholding Pattern Chart

No. of Shareholders

Neuland Laboratories Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
ICICI Prudential Flexicap Fund 269,223 1.81 356.75270,8432026-01-25 02:11:52-0.6%
HSBC Small Cap Fund 161,718 1.43 214.29166,7182025-12-14 08:14:20-3%
Bajaj Finserv Flexi Cap Fund 110,239 2.34 146.08105,4102026-02-23 00:06:484.58%
Mahindra Manulife Multi Cap Fund 73,227 1.6 97.0355,2272026-01-25 02:11:5232.59%
Mahindra Manulife Small Cap Fund 64,583 2.14 85.58N/AN/AN/A
Bandhan Small Cap Fund 54,813 0.38 72.6359,2132025-12-15 06:52:35-7.43%
Sundaram Small Cap Fund 44,855 1.81 59.44N/AN/AN/A
HSBC Multi Cap Fund 36,983 0.95 49.01N/AN/AN/A
Motilal Oswal Business Cycle Fund 34,378 2.44 45.55N/AN/AN/A
ITI Small Cap Fund 27,777 1.38 36.8125,8612026-01-25 02:11:527.41%

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 21
FaceValue 10.0010.0010.0010.0010.00
Basic EPS (Rs.) 202.74233.89127.4549.7462.85
Diluted EPS (Rs.) 202.74233.89127.4549.7462.85
Cash EPS (Rs.) 252.44278.89167.6687.4993.26
Book Value[Excl.RevalReserv]/Share (Rs.) 1181.32993.65769.94650.88608.98
Book Value[Incl.RevalReserv]/Share (Rs.) 1181.97994.31770.59651.52609.63
Revenue From Operations / Share (Rs.) 1144.791208.16923.37737.24726.26
PBDIT / Share (Rs.) 266.48368.31218.28112.16126.29
PBIT / Share (Rs.) 215.67322.03177.3774.1595.52
PBT / Share (Rs.) 268.46311.18167.2463.6981.65
Net Profit / Share (Rs.) 201.63232.61126.7549.4762.50
NP After MI And SOA / Share (Rs.) 201.63232.61126.7549.4762.50
PBDIT Margin (%) 23.2730.4823.6315.2117.38
PBIT Margin (%) 18.8326.6519.2010.0513.15
PBT Margin (%) 23.4525.7518.118.6311.24
Net Profit Margin (%) 17.6119.2513.726.718.60
NP After MI And SOA Margin (%) 17.6119.2513.726.718.60
Return on Networth / Equity (%) 17.0623.4016.467.6010.26
Return on Capital Employeed (%) 16.2329.5720.059.3712.88
Return On Assets (%) 11.9316.3710.354.616.08
Long Term Debt / Equity (X) 0.050.030.070.120.11
Total Debt / Equity (X) 0.080.060.120.270.18
Asset Turnover Ratio (%) 0.730.910.800.700.73
Current Ratio (X) 2.452.151.731.601.49
Quick Ratio (X) 1.621.331.100.870.81
Inventory Turnover Ratio (X) 4.012.011.791.711.88
Dividend Payout Ratio (NP) (%) 6.904.273.926.033.18
Dividend Payout Ratio (CP) (%) 5.513.562.963.412.13
Earning Retention Ratio (%) 93.1095.7396.0893.9796.82
Cash Earning Retention Ratio (%) 94.4996.4497.0496.5997.87
Interest Coverage Ratio (X) 41.4333.9421.5510.729.10
Interest Coverage Ratio (Post Tax) (X) 23.1422.4413.515.735.50
Enterprise Value (Cr.) 15457.068068.902383.791534.952819.28
EV / Net Operating Revenue (X) 10.475.182.001.613.01
EV / EBITDA (X) 44.9616.988.4710.6117.31
MarketCap / Net Operating Revenue (X) 10.555.201.951.392.87
Retention Ratios (%) 93.0995.7296.0793.9696.81
Price / BV (X) 10.226.322.341.583.43
Price / Net Operating Revenue (X) 10.555.201.951.392.87
EarningsYield 0.010.030.070.040.02

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

About the Company - Qualitative Analysis

Neuland Laboratories Ltd. is a Public Limited Listed company incorporated on 07/01/1984 and has its registered office in the State of Telangana, India. Company's Corporate Identification Number(CIN) is L85195TG1984PLC004393 and registration number is 004393. Currently Company is involved in the business activities of Manufacture of medicinal substances used in the manufacture of pharmaceuticals: antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts and esters; glycosides and vegetable alkaloids; chemically pure suger etc.. Company's Total Operating Revenue is Rs. 1476.84 Cr. and Equity Capital is Rs. 12.90 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
Pharmaceuticals11th Floor (5th Office Level), Phoenix IVY Building, Hyderabad Telangana 500033Contact not found
Management
NamePosition Held
Dr. Davuluri Rama Mohan RaoExecutive Chairman
Mr. Davuluri Sucheth RaoVice Chairman & CEO
Mr. Davuluri Saharsh RaoVice Chairman & Mng.Director
Dr. Christopher M CimarustiNon Executive Director
Mr. Homi Rustum KhusrokhanInd. Non-Executive Director
Mr. Prasad Raghava MenonInd. Non-Executive Director
Mr. Sugata SircarInd. Non-Executive Director
Ms. Pallavi Joshi BakhruInd. Non-Executive Director

FAQ

What is the intrinsic value of Neuland Laboratories Ltd and is it undervalued?

As of 18 April 2026, Neuland Laboratories Ltd's intrinsic value is ₹5388.63, which is 57.28% lower than the current market price of ₹12,613.00, suggesting the stock is overvalued. This is calculated using the PE ratio method factoring in ROE (14.8 %), book value (₹1,263), dividend yield (0.10 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of Neuland Laboratories Ltd?

Neuland Laboratories Ltd is trading at ₹12,613.00 as of 18 April 2026, with a FY2026-2027 high of ₹19,748 and low of ₹10,060. The stock is currently in the middle of its 52-week range. Market cap stands at ₹16,182 Cr..

How does Neuland Laboratories Ltd's P/E ratio compare to its industry?

Neuland Laboratories Ltd has a P/E ratio of 90.3, which is above the industry average of 53.84. The premium over industry average may reflect growth expectations or speculative interest.

Is Neuland Laboratories Ltd financially healthy?

Key indicators for Neuland Laboratories Ltd: ROCE of 18.7 % indicates efficient capital utilization. Dividend yield is 0.10 %.

Is Neuland Laboratories Ltd profitable and how is the profit trend?

Neuland Laboratories Ltd reported a net profit of ₹260 Cr in Mar 2025 on revenue of ₹1,477 Cr. Compared to ₹64 Cr in Mar 2022, the net profit shows an improving trend.

Does Neuland Laboratories Ltd pay dividends?

Neuland Laboratories Ltd has a dividend yield of 0.10 % at the current price of ₹12,613.00. The company pays dividends, though the yield is modest.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Neuland Laboratories Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports